191 related articles for article (PubMed ID: 17693067)
1. [Polycythemia vera and JAK-2 mutation in childhood: a case report].
Braconnier O; Monpoux F; Affanetti M; Bérard E; Sirvent N
Arch Pediatr; 2007 Oct; 14(10):1202-5. PubMed ID: 17693067
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
4. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
[TBL] [Abstract][Full Text] [Related]
6. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.
Fleischman RA
Am J Med Sci; 2013 Oct; 346(4):328-30. PubMed ID: 23588264
[TBL] [Abstract][Full Text] [Related]
9. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
10. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
12. How to manage polycythemia vera.
Passamonti F
Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
14. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.
Benedik-Dolničar M; Homan M; Brecelj J
J Pediatr Hematol Oncol; 2012 Apr; 34(3):243-4. PubMed ID: 21552144
[No Abstract] [Full Text] [Related]
17. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
19. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
20. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
